Gastroenterology

Gastroenterology

Volume 157, Issue 1, July 2019, Pages 44-53
Gastroenterology

Reviews and Perspectives
Brief Review
Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics

https://doi.org/10.1053/j.gastro.2019.04.011Get rights and content

Increasing resistance to antibiotics worldwide has adverse effects on the effectiveness of standard therapies to eradicate Helicobacter pylori infection. We reviewed guidelines developed by expert groups in Europe, Canada, and the United States for the treatment of H pylori infection. We compared the recommendations of these guidelines, reconciled them, and addressed the increasing resistance of H pylori to antibiotic therapy regimens. The guidelines recommend bismuth quadruple therapy for first-line treatment, replacing clarithromycin-based triple therapy. There is consensus for concomitant 4-drug therapy as an alternative, especially when bismuth is not available. When therapy is unsuccessful, it is likely due to resistance to clarithromycin, levofloxacin, and/or metronidazole; these drugs, if used previously, should be avoided in subsequent eradication attempts. Second-line therapies should be bismuth quadruple therapy or levofloxacin triple therapy, depending on suspected resistance, reserving rifabutin-based triple and high-dose dual amoxicillin proton pump inhibitor therapy for subsequent treatment attempts. The increasing resistance of H pylori to antibiotic therapy necessitates local availability of susceptibility tests for individuals, and establishment of regional and national monitoring programs to develop evidence-based locally relevant eradication strategies. Further studies into the development of more easily accessible methods of resistance testing, such as biomarker analysis of stool samples, are required. Options under investigation include substituting vonoprazan for proton pump inhibitors, adding probiotics, and vaccine development. Narrow-spectrum antibiotics and new therapeutic targets could be identified based on genomic, proteomic, and metabolomic analyses of H pylori.

Section snippets

Using Antibiotic Susceptibility Data

Each guideline strongly recommends the use of antibiotic susceptibility data whenever available or obtainable. This knowledge would limit inappropriate antibiotic use, thus preventing widespread resistance development in other organisms and reducing costs. For example, using clarithromycin triple therapy instead of concomitant quadruple therapy if the individual’s strain was known to be clarithromycin sensitive or the local resistance rate was <15% would avoid exposure to metronidazole (see

Helicobacter pylori Resistance to Antibiotics Has Become a Global Challenge

Antibiotic overconsumption for medical, veterinary, and livestock purposes is a worldwide problem, responsible for sharp rises in antibiotic resistance in many bacterial species.20 In addition, with the widespread use of macrolides and fluoroquinolones for all indications, there is an associated increased clarithromycin and levofloxacin resistance in H pylori strains in Europe.21 Clarithromycin-resistance is now as high as 30% in Southern Europe, and 50% in China,12, 22 though there are some

Moving the Field Forward

The main therapies used for eradication have been combination broad-spectrum antibiotics, bismuth salts (an ancient remedy for dyspepsia, incidentally found to have anti–H pylori effects),32 and acid inhibitors, which by promoting the logarithmic phase growth of H pylori, render the bacteria more susceptible to antibiotics.33 With declining eradication rates linked to increasing resistance to several key antibiotics, novel therapeutic approaches are essential.

Conclusions

Successful treatment of H pylori infection is an important global public health challenge because it is a preventable cause of gastric cancer, one of the most common fatal malignancies worldwide. In the face of increasing antibiotic resistance, current H pylori guidelines have coalesced around quadruple therapies for initial therapy. Given the principles of antibiotic stewardship, 14-day bismuth quadruple therapy is our choice as first-line therapy when susceptibility testing or regional data

Acknowledgments

Author contributions: Each author contributed to the outline of the study, the drafting of the different components, and the critical revision of the manuscript.

References (63)

  • T. Furuta et al.

    Dual therapy with vonoprazan and amoxicillin is as effective as standard PPI-based triple therapy with amoxicillin and clarithromycin or metronidazole in Japan

    Gastroenterology

    (2016)
  • C. Pasala et al.

    An in silico study: novel targets for potential drug and vaccine design against drug resistant H. pylori

    Microb Pathog

    (2018)
  • A. Lee et al.

    A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain

    Gastroenterology

    (1997)
  • R. Nelson

    Antibiotic development pipeline runs dry. New drugs to fight resistant organisms are not being developed, experts say

    Lancet

    (2003)
  • T.G. Blanchard et al.

    Current status and prospects for a Helicobacter pylori vaccine

    Gastroenterol Clin North Am

    (2015)
  • P. Malfertheiner et al.

    Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomized, placebo-controlled phase 1/2 study

    Lancet Gastroenterol Hepatol

    (2018)
  • M. Zeng et al.

    Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomized, double-blind, placebo-controlled, phase 3 trial

    Lancet

    (2015)
  • P. Sutton

    At last, vaccine-induced protection against Helicobacter pylori

    Lancet

    (2015)
  • K. Sugano et al.

    Kyoto global consensus report on Helicobacter pylori gastritis

    Gut

    (2015)
  • D.Y. Graham

    Editorial: can therapy ever be denied for Helicobacter pylori infection?

    Gastroenterology

    (1997)
  • M. Plummer et al.

    Global burden of gastric cancer attributable to Helicobacter pylori

    Int J Cancer

    (2015)
  • Cancer

  • W.D. Chey et al.

    ACG clinical guideline: treatment of Helicobacter pylori infection

    Am J Gastroenterol

    (2017)
  • P. Malfertheiner et al.

    Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report

    Gut

    (2017)
  • A.C. Ford et al.

    Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis

    Am J Gastroenterol

    (2004)
  • Y.C. Lee et al.

    Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis

    Gastroenterology

    (2016)
  • Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group

    Gut

    (1997)
  • R. Hunt et al.

    Consensus Conference Participants. Canadian Helicobacter pylori Consensus Conference

    Can J Gastroenterol

    (1998)
  • A. Savoldi et al.

    Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions

    Gastroenterology

    (2018)
  • I. Thung et al.

    Review article: the global emergence of Helicobacter pylori antibiotic resistance

    Aliment Pharmacol Ther

    (2016)
  • J. Liao et al.

    Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy

    Helicobacter

    (2013)
  • Cited by (180)

    View all citing articles on Scopus

    Conflicts of interest These authors disclose the following: SFM is doing a research study sponsored by American Molecular Labs related to H pylori resistance testing. PM is doing research with Biocodex, Danone, and Mayoly-Spindler. The remaining author discloses no conflicts.

    View full text